Clinical trial
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
NCT04970901 is registered in ClinicalTrials.gov with ADC Therapeutics S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- Lead sponsor
- ADC Therapeutics S.A.
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- June 17, 2022
- Completion date
- April 30, 2028
- Enrollment
- 154 (actual)
- Sites
- 40
Conditions
As the registry lists them; a condition with its own page is linked.
b-cell non-hodgkin lymphoma, refractory b-cell non-hodgkin lymphoma, relapsed b-cell non-hodgkin lymphoma